Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 108, Issue 12, Pages 5098-5103Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1016277108
Keywords
pain
Categories
Funding
- National Institutes of Health from National Institute on Drug Abuse [DA01533]
Ask authors/readers for more resources
Numerous G protein-coupled receptors (GPCRs) have been shown to form heteromeric receptors in cell-based assays. Among the many heteromers reported in the opioid receptor family are mu/kappa, kappa/delta, and mu/delta. However, the in vivo physiological and behavioral relevance for the proposed heteromers have not yet been established. Here we report a unique example of a ligand, N-naphthoyl-beta-naltrexamine (NNTA) that selectively activates heteromeric mu/kappa-opioid receptors in HEK-293 cells and induces potent antinociception in mice. NNTA was an exceptionally potent agonist in cells expressing mu/kappa-opioid receptors. Intriguingly, it was found to be a potent antagonist in cells expressing only mu-receptors. In the mouse tail-flick assay, intrathecal (i.t.) NNTA produced antinociception that was similar to 100-fold greater than by intracerebroventricular (i.c.v.) administration. The.-antagonist, norBNI, decreased the i.t. potency, and the activity was virtually abolished in mu-opioid receptor knockout mice. No tolerance was induced i.t., but marginal tolerance (3-fold) was observed via the i.c.v. route. Moreover, NNTA produced neither significant physical dependence nor place preference in the ED50 dose range. Taken together, this work provides an important pharmacologic tool for investigating the in vivo functional relevance of heteromeric mu/kappa-opioid receptors and suggests an approach to potent analgesics with fewer deleterious side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available